Abbott Laboratories（ABT）股票分析ABTAbbott Laboratories

Abbott Laboratories is a global healthcare company. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. It serves people in more than 160 countries. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Abbott Laboratories is a good buy right now due to its current price of $103.70, which is below the analyst price targets of $120 and $127, indicating significant upside potential. The company is also experiencing a positive shift with a planned spin-off of its nutrition business, which is expected to enhance margins and focus on higher-growth medical technologies. Additionally, the RSI is at 59.75, suggesting that the stock is nearing overbought territory but still has room for growth. However, the main risk is the debt-to-equity ratio, which has increased to 64.60%, indicating potential financial strain if not managed properly.

20 analysts cover ABT: 13 rate it Buy, 7 Hold and 0 Sell. The average price target is 148.11.